MP02-12 PROSTATE-SPECIFIC EXTRACELLULAR VESICLES AS A NOVEL BIOMARKER IN HUMAN PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2016MP02-12 PROSTATE-SPECIFIC EXTRACELLULAR VESICLES AS A NOVEL BIOMARKER IN HUMAN PROSTATE CANCER Yong Hyun Park, Hyun Woo Shin, Ae Ryang Jung, Oh Sung Kwon, Jaesung Park, and Ji Youl Lee Yong Hyun ParkYong Hyun Park More articles by this author , Hyun Woo ShinHyun Woo Shin More articles by this author , Ae Ryang JungAe Ryang Jung More articles by this author , Oh Sung KwonOh Sung Kwon More articles by this author , Jaesung ParkJaesung Park More articles by this author , and Ji Youl LeeJi Youl Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1884AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Extracellular vesicles (EVs) may play an important role in cancer development and progression. However, few studies have investigated the prognostic relevance of EVs in prostate cancer (PCa). We aimed to investigate the prognostic potential of prostate-specific EVs in PCa patients. METHODS Plasma and prostate tissue were collected from patients who underwent surgery for PCa (n=82) or benign prostatic hyperplasia (BPH, n=28). To analyze the quantity of EVs in prostatic tissue, we performed transmission electron microscopy (TEM), immuno-TEM with CD63 and prostate-specific membrane antigen (PSMA) antibodies, and immunofluorescence staining. After EV isolation from plasma using an aqueous two-phase system, CD63 and PSMA concentration was measured using ELISA kits. Relationship between plasma EV concentration and clinicopathologic outcomes were analyzed. RESULTS PSMA-positive areas in prostate tissue differed in patients with BPH, and low-, intermediate-, and high-risk PCa (2.4, 8.2, 17.5, 26.5%, p<0.001; Fig.1). Plasma concentration of PSMA-positive EVs was different among patients with BPH, and low-, intermediate-, and high-risk PCa (21.9, 43.4, 49.2, 59.9 ng/mL, p<0.001), and ROC curve analysis indicated that plasma PSMA-positive EV concentration differentiated PCa from BPH (AUC 0.943, 95% confidence interval 0.866-0.983; Fig.2). Patients with lower levels of plasma prostate-specific EVs had greater prostate volume (50.2 vs. 33.4 cc, p<0.001) and lower pathologic Gleason score (p=0.025). During the median follow-up of 18 months, patients with a lower levels of prostate-specific EVs tended to have a lower risk of biochemical failure than those with higher levels of prostate-specific EVs (p=0.085). CONCLUSIONS Plasma prostate-specific EVs have a potential role in differentiating PCa from BPH. In patients with PCa, lower levels of plasma prostate-specific EVs were associated with favorable pathologic features and better biochemical recurrence-free survival. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e13-e14 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Yong Hyun Park More articles by this author Hyun Woo Shin More articles by this author Ae Ryang Jung More articles by this author Oh Sung Kwon More articles by this author Jaesung Park More articles by this author Ji Youl Lee More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...